Geoffrey A. Swire
Chief Operating Officer at ALLENA PHARMACEUTICALS, INC.
Profile
Geoffrey A.
Swire is currently the COO & Senior Vice President-Corporate Development at Allena Pharmaceuticals, Inc. He previously worked as the Head-Program & Portfolio Management at Genzyme Corp.
and as the Head-Business Development & Alliance Management at Radius Health, Inc. He completed his undergraduate degree at Dartmouth College and his graduate degree at Harvard University.
Geoffrey A. Swire active positions
Companies | Position | Start |
---|---|---|
ALLENA PHARMACEUTICALS, INC. | Chief Operating Officer | 10/11/2020 |
Former positions of Geoffrey A. Swire
Companies | Position | End |
---|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
RADIUS HEALTH, INC. | Corporate Officer/Principal | - |
Training of Geoffrey A. Swire
Dartmouth College | Undergraduate Degree |
Harvard University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ALLENA PHARMACEUTICALS, INC. | Health Technology |
Private companies | 2 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Radius Health, Inc.
Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Geoffrey A. Swire